HAYWARD, Calif., Feb. 28, 2025 /PRNewswire/ — Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the commencement of Investigational New Drug (IND)-enabling studies of ABI-201, a potential first-in-class AAV vector that delivers…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.